153 related articles for article (PubMed ID: 38730243)
1. The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion.
Uslu U; Sun L; Castelli S; Finck AV; Assenmacher CA; Young RM; Chen ZJ; June CH
Nat Commun; 2024 May; 15(1):3933. PubMed ID: 38730243
[TBL] [Abstract][Full Text] [Related]
2. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
3. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.
Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; Glez-Vaz J; Casares N; Rodríguez-García E; Hommel M; González-Aseguinolaza G; Uranga-Murillo I; Pardo J; Alkorta G; Melero I; Lasarte J; Hervas-Stubbs S
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34810235
[TBL] [Abstract][Full Text] [Related]
4. Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.
Xu XJ; Song DG; Poussin M; Ye Q; Sharma P; Rodríguez-García A; Tang YM; Powell DJ
Oncotarget; 2016 Dec; 7(50):82354-82368. PubMed ID: 27409425
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol Esterification Enzyme Inhibition Enhances Antitumor Effects of Human Chimeric Antigen Receptors Modified T Cells.
Zhao L; Li J; Liu Y; Kang L; Chen H; Jin Y; Zhao F; Feng J; Fang C; Zhu B; Ding S; Yu L; Wei Y; Zhou J
J Immunother; 2018; 41(2):45-52. PubMed ID: 29252915
[TBL] [Abstract][Full Text] [Related]
7. Effects of cryopreservation on chimeric antigen receptor T cell functions.
Xu H; Cao W; Huang L; Xiao M; Cao Y; Zhao L; Wang N; Zhou J
Cryobiology; 2018 Aug; 83():40-47. PubMed ID: 29908946
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy.
Stock S; Schmitt M; Sellner L
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835562
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-23 engineering improves CAR T cell function in solid tumors.
Ma X; Shou P; Smith C; Chen Y; Du H; Sun C; Porterfield Kren N; Michaud D; Ahn S; Vincent B; Savoldo B; Pylayeva-Gupta Y; Zhang S; Dotti G; Xu Y
Nat Biotechnol; 2020 Apr; 38(4):448-459. PubMed ID: 32015548
[TBL] [Abstract][Full Text] [Related]
10. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement.
Zhang Y; Zhang C; Zhou J; Zhang J; Chen X; Chen J; Wang P; Sun X; Lou X; Qi W; Kang L; Yu L; Wu D; Li C
Front Immunol; 2021; 12():552429. PubMed ID: 33717057
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
Cummins KD; Gill S
Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
14. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
Zhang H; Hu Y; Shao M; Teng X; Jiang P; Wang X; Wang H; Cui J; Yu J; Liang Z; Ding L; Han Y; Wei J; Xu Y; Li X; Shan W; Shi J; Luo Y; Qian P; Huang H
J Hematol Oncol; 2021 Jul; 14(1):113. PubMed ID: 34289897
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
[TBL] [Abstract][Full Text] [Related]
17. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
Ko AH; Jordan AC; Tooker E; Lacey SF; Chang RB; Li Y; Venook AP; Tempero M; Damon L; Fong L; O'Hara MH; Levine BL; Melenhorst JJ; Plesa G; June CH; Beatty GL
Mol Ther; 2020 Nov; 28(11):2367-2378. PubMed ID: 32730744
[TBL] [Abstract][Full Text] [Related]
18. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Nonviral
Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
Front Immunol; 2021; 12():802705. PubMed ID: 35082789
[TBL] [Abstract][Full Text] [Related]
20. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
